Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

BackgroundImmune checkpoint inhibitors (ICIs) are widely used in lung cancer treatment; however, immune-related adverse events (irAEs) remain an important safety-related research topic. Currently, there is a lack of comprehensive bibliometric analyses specifically addressing irAEs in lung cancer.MethodsThis study utilized the Web of Science Core Collection (WoSCC) and PubMed databases to retrieve literature on irAEs associated with ICIs in lung cancer from 2016 to 2025. Among the 1, 792 eligible records from WoSCC, bibliometric and visualization analyses were conducted using tools such as Bibliometrix and CiteSpace (v7.0).